ARA 290 10 mg vials - When out of stock, it takes 6-8 weeks to get.

ARA-290 is a small peptide derived from the helix beta domain or erythropoietin. EPO has long been know to exhibit actions beyond the stimulation of red blood cell production in bone marrow. The glycoprotein, which is made in the kidney, has been found to stimulate blood vessel growth, promote cell survival, alter blood pressure, and produce neuroprotective effects in diabetic neuropathy. ARA-290 offers the neuroprotective and pain relieving effects of EPO without stimulating red blood cell production. ARA-290 has completed phase II trials and is in preparation to enter phase III trials for a variety of applications in diabetes and the autoimmune sarcoidosis. Right now the peptide is of active interest for its ability to control neuropathic pain, but it is also under investigation as a potential stimulator of wound repair in chronic diabetes, as an immune modulatory peptide, and as a potential treatment for systemic lupus erythematosus.